Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271504 · ClinicalTrials.gov registry record · Phase 1
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
A Phase 1 study of Hepatocellular Carcinoma, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT01271504 is a Phase 1 study of Hepatocellular Carcinoma that has completed, run by Eisai. The registered enrollment target is 102 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT01271504, a Phase 1 study of Hepatocellular Carcinoma, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050 is administered with Sorafenib.
Conditions Studied
Interventions
- DRUG Sorafenib
Study Locations (20)
Other
- - Brussels
- - Brussels
- - Leuven
- - Modena
- - Pavia
- - Madrid
- - Madrid
- - Madrid
- - Madrid
- - Dnipropetrovsk
- - Donetsk
- - Kharkiv
Florida
- - Fort Myers
- - St. Petersburg
Ohio
- - Cincinnati
- - Toledo
Arizona
- - Tucson
North Carolina
- - Chapel Hill
Tennessee
- - Nashville
Milano
- - Rozzano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2011-07-19 |
| Est. Completion | 2015-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01271504
The ClinicalTrials.gov registry entry for NCT01271504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (60% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib is the first listed.
NCT01271504 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01271504 about?
NCT01271504 is a clinical study titled "E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma". The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050 is administered with Sorafenib.
What is the current status of trial NCT01271504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2011-07-19. Estimated completion is 2015-06-23.
What conditions does trial NCT01271504 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01271504?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01271504?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01271504 being conducted?
This trial has 20 study locations across Arizona, Florida, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.